U.S. markets close in 1 hour 45 minutes

Bluejay Diagnostics, Inc. (BJDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4650+0.0250 (+5.68%)
As of 01:56PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.4400
Bid0.4650 x 800
Ask0.4800 x 1200
Day's Range0.4200 - 0.4875
52 Week Range0.2780 - 1.8300
Avg. Volume57,862
Market Cap9.371M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BJDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bluejay Diagnostics, Inc.
    Daily – Vickers Top Insider Picks for 05/05/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Simply Wall St.

    Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65k

    Insiders who acquired US$183k worth of Bluejay Diagnostics, Inc.'s ( NASDAQ:BJDX ) stock at an average price of US$1.09...

  • GlobeNewswire

    Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

    ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2022. “The last quarter focused on increasing awareness of Bluejay’s Symphony IL-6 test by directly engaging the

  • GlobeNewswire

    Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022, at the Lotte Palace Ho